IMRIS receives licensing to incorporate MRI core technology into VISIUS Surgical Theatre in Canada

Core MRI technology provides most advanced scanners for highest intraoperative image quality and best workflow available

IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that the Company has received Health Canada licensing to incorporate next generation MRI core technology into the VISIUS Surgical Theatre for sales and marketing in the country.

This newest imaging technology, based on the Siemens Aera 1.5T (Tesla) and Skyra 3.0T MRI scanners, helps IMRIS deliver even better image quality, faster 3D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI). The Company received United States Food and Drug Administration (FDA) clearance for these advancements in February 2014 and last month received CE mark authorization in Europe.

"Hospitals who adopt this technology in our VISIUS solution will have access to the highest quality MR applications and images within the operating room setting," said IMRIS President and CEO Jay D. Miller. "This latest and unequaled imaging technology in the hands of neurosurgeons is improving patient outcomes and making newer minimally-invasive treatment options for brain tumors, epilepsy and other therapies work better."

Inside a VISIUS Surgical Theatre equipped with high-field iMRI, surgeons have on-demand access to real-time data and state-of-the-art imaging during the procedure as the scanner uniquely moves on ceiling-mounted rails. The Company also designs and manufactures proprietary intraoperative CTs, head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment.